Table 2_Megestrol acetate in the management of cancer cachexia: a prospective quasi-experi

A dataset from a prospective quasi-experimental study investigating the efficacy of megestrol acetate in 97 patients with cancer cachexia. The data includes primary endpoints like body weight, BMI, skeletal muscle mass, and fat mass, along with secondary endpoints such as inflammatory markers and quality-of-life scores. The dataset was authored by Xiaoting Zhong and last updated on 2026-04-21.

Use Cases

• Analyze changes in nutritional indices like body weight and BMI based on treatment group assignment.
• Investigate the relationship between megestrol acetate treatment and reductions in cancer-related fatigue domain scores.
• Compare inflammatory marker levels (e.g., IL-6) between treatment and control groups over the 2-month intervention.
• Study the preservation of skeletal muscle mass in cancer cachexia patients receiving pharmacological intervention.

Strengths

• Data originates from a prospective study with 97 patients, providing a defined sample size.
• Includes multi-dimensional endpoints covering nutritional, inflammatory, immune, and patient-reported outcomes.
• Dataset is shared under a permissive CC-BY-4.0 license, facilitating reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The study is described as non-randomized, which may limit causal inference.

Provenance

Source

figshare, author Xiaoting Zhong

Collection Method

Data collected from a prospective, non-randomized clinical study.

Time Range

Study intervention period was 2 months.

Freshness

Last updated 2026-04-21 04:22:23; freshness should be verified.